Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Codiak revokes $86m IPO filing
Codiak BioSciences, based on research at the universities of Gothenburg and Texas, hoped to raise $86m in an initial public offering but has now withdrawn those plans.
Morphic takes more money in $104m IPO
Small molecule therapeutic developer Morphic, based on research at Harvard Medical School, has boosted its initial public offering from $90m to nearly $104m.
Morphic shapes $90m initial public offering
Morphic began trading on the Nasdaq Global Market yesterday after issuing 6 million shares priced at $15 each, providing exits to AbbVie, GSK, Novo, Pfizer, Schrödinger and ShangPharma.
Personalis exemplifies $140m IPO
Having initially targeted $115m in proceeds, the genome sequencing spinout of Stanford has closed its offering at $140m after a full exercise of the overallotment option.
Atreca takes $125m in initial public offering
Stanford's Atreca floated in the middle of its range and will use the funding to advance its lead cancer immunotherapeutic canadidate through the clinic.
Personalis embodies $115m IPO
Personalis has filed to list on the Nasdaq Global Market through an offering that would come eight years after the genome sequencing platform was spun out of Stanford University.
OssDsign surpasses IPO target
Karolinska Development-backed regenerative implant producer OssDsign has booked $15.8m after selling out the original issue for its forthcoming listing, and is now looking to generate up to $2.4m from the overallotment.
Bicycle Therapeutics squares $60.7m IPO circle
Cambridge Innovation Capital has celebrated an exit as Bicycle Therapeutics successfully lists in the US.

Other News

NextCure executes $75m in initial public offering
The immunotherapy developer, which is exploits Yale University research and counts Eli Lilly, Pfizer, Taiho and Ping An as investors, floated in the middle of its range after raising $160m in venture funding.
OssDsign prepares public listing
Regenerative implant producer OssDsign, based on research at Karolinska University Hospital and Uppsala University, hopes to list on the Nasdaq First North and raise $15.8m.
Codiak loads up IPO filing
Exosome therapeutics developer Codiak BioSciences, exploiting technology developed by researchers at the universities of Gothenburg and Texas, is eyeing up to $86.3m in an IPO.
Bicycle Therapeutics to go for a spin on Nasdaq
Cambridge Innovation Capital is in line for an exit as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.
Willow Biosciences follows public path
Willow Biosciences is the result of a three-way merger between University of Calgary spinout Epimeron, BioCan Technologies and CSE-listed Makena Resources.
Oxford Nanopore sets sights on IPO
The Oxford University genetic sequencing spinout is reportedly mulling an IPO that would provide exits to investors including commercialisation firm IP Group.

Editor's Picks

Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg